|
WO2020260270A1
|
|
Il2 agonists
|
|
WO2020234410A1
|
|
Therapeutic rna for ovarian cancer
|
|
WO2020182869A1
|
|
Therapeutic rna for prostate cancer
|
|
WO2020144295A1
|
|
Localized administration of rna molecules for therapy
|
|
WO2021058091A1
|
|
Treatment involving therapeutic antibody and interleukin-2 (il2)
|
|
CA3106858A1
|
|
Il2 agonists
|
|
WO2021008708A1
|
|
Method for determining at least one parameter of a sample composition comprising nucleic acid, such as rna, and optionally particles
|
|
WO2021001023A1
|
|
Rna formulations suitable for therapy
|
|
WO2020200481A1
|
|
Treatment involving interleukin-2 (il2) and interferon (ifn)
|
|
WO2020200472A1
|
|
Preparation and storage of liposomal rna formulations suitable for therapy
|
|
AU2019235424A1
|
|
5'-cap-trinucleotide- or higher oligonucleotide compounds and their uses in stabilizing RNA, expressing proteins and in therapy
|
|
AU2019219200A1
|
|
Treatment using cytokine encoding RNA
|
|
CN111601605A
|
|
Formulations for administration of RNA
|
|
KR20200100619A
|
|
Preparation and storage of liposomal RNA formulations suitable for therapy
|
|
EP3681993A1
|
|
Rna replicon for reprogramming somatic cells
|
|
CN111315760A
|
|
Methods for enhancing RNA expression in cells
|
|
WO2020020444A1
|
|
Individualized vaccines for cancer
|
|
WO2018172426A1
|
|
Methods and compositions for stimulating immune response
|
|
KR20190027832A
|
|
Selection of neo-epitopes as disease-specific targets for treatment with improved efficacy
|
|
WO2018224166A1
|
|
Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
|
